Jessica Y. Bae
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jessica Y. Bae has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Carsten P Bs Schmidt
Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA
1 shared publication- Carsten P. Schmidt
Elson S. Floyd College of Medicine, Spokane, Washington, USA
1 shared publication Connie J Chen
Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA
1 shared publicationConnie J. Chen
1 shared publicationJessica A. Hellyer
San Juan Cancer Center, Montrose Regional Health, Montrose, Colorado, USA
1 shared publication- Josephine Kamtai Dermawan
Department of Pathology and Laboratory Medicine Cleveland Clinic Cleveland Ohio USA
1 shared publication
Latest Publications
- Open Access
- 23 October 2026
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 44
Vision loss following tranexamic acid injection during an elective sinus surgery
- 23 October 2026
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 44
Open AccessVision loss following tranexamic acid injection during an elective sinus surgery
- 1 April 2026
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
Choroidal Neovascularization as a Postpartum Complication of Gestational Hypertension: A Case Report
Purpose: To report a case of choroidal neovascularization in a patient with gestational hypertension using optical coherence tomography angiography (OCT-A). Methods: This is a case report. Results: A 32-year-old woman with gestational hypertension without pre-eclampsia presented with new choroidal neovascularization two months postpartum (visual acuity of 20/70). Subretinal hemorrhage resolved after injection of intravitreal bevacizumab, and regression of choroidal neovascularization was visualized by optical coherence tomography angiography. Treatment was repeated 7 months later for recurrence of hemorrhage, and she remained stable with visual acuity of 20/20 at 12-month follow-up. Conclusion: Practitioners should be aware that patients with gestational hypertension may develop delayed and visually significant choroidal neovascularization. Optical coherence tomography angiography serves as a valuable, noninvasive tool for diagnosis and follow-up in this population. Early recognition and prompt treatment can lead to favorable visual outcomes.
- 1 April 2026
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
Choroidal Neovascularization as a Postpartum Complication of Gestational Hypertension: A Case Report
Purpose: To report a case of choroidal neovascularization in a patient with gestational hypertension using optical coherence tomography angiography (OCT-A). Methods: This is a case report. Results: A 32-year-old woman with gestational hypertension without pre-eclampsia presented with new choroidal neovascularization two months postpartum (visual acuity of 20/70). Subretinal hemorrhage resolved after injection of intravitreal bevacizumab, and regression of choroidal neovascularization was visualized by optical coherence tomography angiography. Treatment was repeated 7 months later for recurrence of hemorrhage, and she remained stable with visual acuity of 20/20 at 12-month follow-up. Conclusion: Practitioners should be aware that patients with gestational hypertension may develop delayed and visually significant choroidal neovascularization. Optical coherence tomography angiography serves as a valuable, noninvasive tool for diagnosis and follow-up in this population. Early recognition and prompt treatment can lead to favorable visual outcomes.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Oncological Medicine
- Vol. 2026 (1)
Primary Pulmonary NUT Carcinoma: A Case Illustration of Therapeutic Challenges and Review of Emerging Targeted Therapies
Background: Pulmonary NUT carcinoma is a rare but highly aggressive malignancy with poor prognosis. It typically affects younger patients with no smoking history. Given its rapid progression, it is crucial to consider it as a differential diagnosis in a poorly differentiated thoracic mass to ensure timely diagnosis and management. Case Presentation: We report a case of primary pulmonary NUT carcinoma diagnosed in a 59‐year‐old male with a never‐smoking history during routine screening for possible occupational asbestos exposure. The preliminary diagnosis of metastatic keratinizing squamous cell carcinoma was later reclassified as NUT carcinoma by immunohistochemistry. Next generation sequencing of ctDNA showed CDKN2A mutation. The therapeutic course was complicated by several hypersensitivity reactions to first line treatments. Due to rapidly deteriorating clinical status, the patient was no longer eligible for a BET inhibitor clinical trial and died approximately 5 months after diagnosis. Conclusion: Due to its rarity and poor therapeutic response, there is currently no established standard of treatment for pulmonary NUT carcinoma. Timely and accurate diagnosis remains challenging due to its nonspecific presentation and rarity, resulting in low clinical suspicion, especially in patients outside the typical demographic. Common first‐line treatments include platinum‐based regimens in combination with etoposide or paclitaxel. Several clinical trials of BET and histone deacetylase inhibitors are active, and clinicians are encouraged to enroll patients to maximize survival outcomes.
- 1 January 2026
- Published by Wiley in Case Reports in Oncological Medicine
- Vol. 2026 (1)
Open AccessPrimary Pulmonary NUT Carcinoma: A Case Illustration of Therapeutic Challenges and Review of Emerging Targeted Therapies
Background: Pulmonary NUT carcinoma is a rare but highly aggressive malignancy with poor prognosis. It typically affects younger patients with no smoking history. Given its rapid progression, it is crucial to consider it as a differential diagnosis in a poorly differentiated thoracic mass to ensure timely diagnosis and management. Case Presentation: We report a case of primary pulmonary NUT carcinoma diagnosed in a 59‐year‐old male with a never‐smoking history during routine screening for possible occupational asbestos exposure. The preliminary diagnosis of metastatic keratinizing squamous cell carcinoma was later reclassified as NUT carcinoma by immunohistochemistry. Next generation sequencing of ctDNA showed CDKN2A mutation. The therapeutic course was complicated by several hypersensitivity reactions to first line treatments. Due to rapidly deteriorating clinical status, the patient was no longer eligible for a BET inhibitor clinical trial and died approximately 5 months after diagnosis. Conclusion: Due to its rarity and poor therapeutic response, there is currently no established standard of treatment for pulmonary NUT carcinoma. Timely and accurate diagnosis remains challenging due to its nonspecific presentation and rarity, resulting in low clinical suspicion, especially in patients outside the typical demographic. Common first‐line treatments include platinum‐based regimens in combination with etoposide or paclitaxel. Several clinical trials of BET and histone deacetylase inhibitors are active, and clinicians are encouraged to enroll patients to maximize survival outcomes.